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Objectives: The aim of this study was to explore the association between the use of statins and esophageal
cancer in Taiwan.
Methods: We designed a casecontrol study using database from the Taiwan National Health Insurance
program. In all, 549 patients (cases) aged 20 years or older diagnosed recently with esophageal cancer, from
2000 to 2009, and 2,196 subjects (controls) without esophageal cancer participated in this study. The
association between esophageal cancer and the use of statins and other co-morbidities was measured.
Results: After adjustment for covariates, multivariate logistic regression showed that patients with a
cumulative duration of ]12 months of using atorvastatin might have a reduced risk of esophageal cancer,
compared with those who did not use statins (odds ratio [OR] 0.14, 95% confidence interval [CI] 0.040.56).
The other statins could not show a significant association with esophageal cancer. Age (OR 1.01, 95% CI
1.001.01), alcoholism (OR 3.83, 95% CI 3.014.89), and esophageal diseases (OR 4.60, 95% CI 3.466.12)
were independent factors significantly associated with esophageal cancer.
Conclusions: Use of atorvastatin ]12 months may correlate with an 86% reduction of esophageal cancer risk.
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Introduction
According to global estimates in 2008, esophageal cancer
was the eighth commonly diagnosed cancer (482,300 new
cases) and the sixth leading cause of cancer deaths
(406,800 death cases) (1, 2). In 2010, esophageal cancer
was the eighth leading cause of cancer deaths in Taiwan,
with a mortality rate of 6.8 per 100,000 persons (1,563
fatalities, 3.8% of the total) (3).
The etiology of esophageal cancer remains inconclu-
sive, but a number of risk factors have been reported to be
associated with esophageal cancer in previous literature,
including Barrett’s esophagus, gastroesophageal reflux
disease, obesity, cigarette smoking, excess alcohol con-
sumption, use of spicy foods and hot drinks, and low
intake of fresh fruit and vegetables (47). On the contrary,
Helicobacter pylori infection and use of aspirin and non-
steroidal anti-inflammatory drugs (NSAIDs) correlate
with decreased risk of esophageal cancer (46).
3-Hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) re-
ductase inhibitors, known as statins, are commonly
used to reduce the cholesterol level and to further
decrease the risk of cardiovascular disease.
Recently, two in vitro studies demonstrated that statins
have the ability to inhibit proliferation and further
increase apoptosis of esophageal adenocarcinoma cells
(8, 9). A casecontrol study by Nguyen et al. in the
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United States showed that use of statins correlates with
45% reduction of esophageal cancer risk in patients
with Barrett’s esophagus (95% confidence interval [CI]
0.360.86) (10).
To date, there has been no study available on the
association between the use of statins and esophageal
cancer in Taiwan. With comprehensive understanding
of esophageal cancer, new preventive strategies can
be developed to help improve treatment outcomes and
reduce related fatalities. Therefore, we conducted this
casecontrol study using the National Health Insurance
(NHI) program database in Taiwan to explore the
following questions: (1) Is there an association between
use of statins and esophageal cancer? (2) What are the
effects of other co-morbidities and medications on the
risk of esophageal cancer?
Materials and methods
Data sources
This casecontrol study used data from the NHI program
in Taiwan, the details of which can be found in previous
studies (1114). To ensure patient privacy, all personal
identification data on files related to this study were
replaced with surrogate identification numbers. This
study was exempt from full review by the Institutional
Review Board.
Inclusion criteria
For subjects, we selected those who were diagnosed
recently with esophageal cancer (International Classifica-
tion of Diseases Ninth Revision-Clinical Modification,
ICD-9 codes 150.X and A-code A090) during the period
of 20002009 and aged 20 years or older at the time of
diagnosis. The date of diagnosis of esophageal cancer was
defined as the index date for each case. For each case of
esophageal cancer, we randomly selected, from the same
dataset, four subjects who were frequency matched for
sex, age (per 5 years) and index date as controls. We
excluded those subjects with esophageal cancer or any
other cancer (ICD-9 codes 140208 and A-code A08x-
A14x) before the index date.
Potential co-morbidities and medications associated
with esophageal cancer risk
To enumerate the effects of potential co-morbidities and
medications on the risk of esophageal cancer, the follow-
ing co-morbidities were included before the index date:
obesity (ICD-9 codes 278.00, 278.01, and A-code A183),
esophageal diseases (ICD-9 codes 530.x and 947.2),
H. pylori infection (ICD-9 codes 041.86), alcoholism
(ICD-9 codes 303, 305.00, 305.01, 305.02, 305.03, V11.3,
and A-code A215), and tobacco use (ICD-9 codes 305.1).
Medication history of six commercially available statins
before the index date, including simvastatin, lovastatin,
pravastatin, fluvastatin, atorvastatin, and rosuvastatin,
were included. The other medications included were as
follows: non-statin lipid-lowering drugs, proton pump
inhibitors, histamine-2 receptor antagonists, aspirin,
other NSAIDs, and cyclooxygenase-2 inhibitors (COX-2
inhibitors).
Statistical analysis
We demonstrated the differences in demographic factors,
co-morbidities, and medications between the esophageal
cancer cases and the controls by the Chi-square test,
t-test, and Fisher’s exact test. The significant variables
were further included in the multivariate logistic regres-
sion analysis to measure odds ratio (OR) and 95% CI for
esophageal cancer. The statistical significance level was
set at a probability value of B0.05 (SAS software version
9.1, SAS Institute Inc., Cary, North Carolina).
Results
Baseline characteristics of the study population
In this study, 549 cases with esophageal cancer and 2,196
subjects as controls without esophageal cancer were
presented. Table 1 compares the demographic character-
istics, co-morbidities, and medications between esopha-
geal cancer cases and controls. The cases had higher
proportions of alcoholism, esophageal diseases, use of
proton pump inhibitors, use of histamine-2 receptor
antagonists, use of other NSAIDs, and use of COX-2
inhibitors.
Esophageal cancer associated with use of statins
and covariates
After adjustment for covariates, multivariate logistic
regression showed the adjusted OR of esophageal cancer
as 0.66 (95% CI 0.450.95) for the group that uses statins,
when compared with the group that does not use statins.
Age (OR 1.01, 95% CI 1.001.01), alcoholism (OR 3.83,
95% CI 3.014.89), esophageal diseases (OR 4.60, 95% CI
3.466.12), and use of proton pump inhibitors (OR 3.83,
95% 3.014.89) were independent factors significantly
associated with esophageal cancer (Table 2).
Sub-analysis of the association between the six
types of statins and esophageal cancer
In sub-analysis, patients with a cumulative duration
of using atorvastatin ]12 months had a reduced risk
of esophageal cancer, compared with those who does not
use statins (OR 0.14, 95% CI 0.040.56). The other statins
did not show a significant association with esophageal
cancer (Table 3).
Discussion
A growing body of epidemiologic evidence has shown
that use of statins correlates with risk reduction of some
Shih-Wei Lai et al.
2
(page number not for citation purpose)
Citation: Libyan J Med 2012, 7: 18830 - http://dx.doi.org/10.3402/ljm.v7i0.18830
digestive cancers, including those of stomach, colon
rectum, liver, and pancreas (1518). To the best of our
knowledge, the association between the use of statins and
esophageal cancer is still under investigation. In this
study, we found patients using statins had an overall 34%
risk reduction of esophageal cancer, when compared with
the group not using statins. In sub-analysis, atorvastatin
could reduce 86% risk of esophageal cancer when used for
]12 months. These results are consistent with a previous
study by Nguyen et al. (10), which suggested that use of
statins for more than 12 months can correlate with 48%
risk reduction of esophageal cancer in patients with
Barrett’s esophagus (95% CI 0.300.91) (10). Although
the mechanism behind the correlation of the use of statins
with decreased risk of esophageal cancer is not well
elucidated, in vitro studies have demonstrated that statins
have the effects of decreasing viability, decreasing pro-
liferation, and increasing apoptosis of human esophageal
adenocarcinoma cells (8, 9). More studies are needed to
explore the links between esophageal cancer and the use
of statins to gain a better understanding on the protective
or harmful effects of statins on esophageal cancer risk.
Contrary to previous studies (19, 20), we found that
proton pump inhibitors might be associated with in-
creased risk of esophageal cancer (OR 3.83). In our
opinion, this does not mean that proton pump inhibitors
potentially cause esophageal cancer. Instead, patients
treated with proton pump inhibitors might be those
with early undiagnosed esophageal cancer who initially
present with esophageal symptoms and use proton pump
inhibitors. That is, proton pump inhibitors may mask
the diagnosis of esophageal cancer. We also found that
esophageal diseases correlate with increased risk of
esophageal cancer (OR 4.60). Thus, these findings should
alert clinicians to be more cautious of the potential risk of
esophageal cancer when patients present with esophageal
symptoms.
There are a number of limitations to this study.
The first concern is that we cannot separately examine
squamous cell cancer from adenocarcinoma of the
esophagus because of inherent limitation of the dataset
we used. This is a fundamental issue for analysis because
these two cancers may be associated with different risk
Table 1. Comparison by demographic factors and other








Women 156 (7.10) 39 (7.10)
Men 2040 (92.9) 510 (92.9)
Age (Mean and SD,
years)*
60.3 (13.3) 60.9 (12.9) 0.33
Co-morbidities
Alcoholism 31 (1.41) 78 (14.2) B0.0001
Tobacco use
disorder
37 (1.68) 9 (1.64) 0.94
Obesity$ 4 (0.18) 3 (0.55) 0.15
Esophageal
diseases
128 (5.83) 178 (32.4) B0.0001
Helicobacter
pylori infection
10 (0.46) 3 (0.55) 0.78
Medications
Use of statins 238 (10.8) 49 (8.93) 0.19
Use of non-statin,
lipid-lowering drugs
209 (9.52) 58 (10.6) 0.46
Use of proton
pump inhibitors
284 (12.9) 262 (47.7) B0.0001
Use of histamine-2
receptor antagonists
1139 (51.9) 391 (71.2) B0.0001
Use of aspirin 715 (32.6) 187 (34.1) 0.50
Use of other
NSAIDs
2021 (92.0) 526 (95.8) 0.002
Use of COX-2
inhibitors
534 (24.3) 157 (28.6) 0.04
Data are presented as the number of subjects in each group,
with percentages given in parentheses. Chi-square test, *t-test,
and $Fisher’s exact test comparing subjects with and without
esophageal cancer.
Table 2. Crude and adjusted odds ratios and 95% confidence









Men 1.00 (0.701.44) 0.88 (0.591.33)
Age (per year) 1.00 (1.001.01) 1.01 (1.001.01)
Co-morbidities (yes vs. no)
Alcoholism 11.6 (7.5417.7) 3.83 (3.014.89)
Esophageal diseases 7.75 (6.029.98) 4.60 (3.466.12)
Medications (use vs. non-use)
Statins 0.81 (0.581.11) 0.66 (0.450.95)
Proton pump inhibitors 6.15 (4.997.57) 3.83 (3.014.89)
Histamine-2 receptor
antagonists
2.30 (1.882.81) 1.21 (0.951.53)
Other NSAIDs 1.98 (1.273.09) 1.21 (0.751.97)
COX-2 inhibitors 1.25 (1.011.54) 0.80 (0.621.04)
Adjusted for sex, age, esophageal diseases, alcoholism, statins,
proton pump inhibitors, histamine-2 receptor antagonists, other
NSAIDs, and COX-2 inhibitors.
Esophageal cancer and atorvastatin
Citation: Libyan J Med 2012, 7: 18830 - http://dx.doi.org/10.3402/ljm.v7i0.18830 3
(page number not for citation purpose)
factors (6, 7). This indicates a future direction for
research into the effects of statins on squamous cell
cancer and adenocarcinoma of the esophagus. Second,
lack of control for potentially confounding factors,
including use of spicy foods and hot drinks, low intake
of fresh fruit and vegetables, is also because of inherent
limitation of this dataset. Third, the number of subjects
for each of the individual statins is relatively small.
Particularly, only 19 cases suffered from esophageal
cancer in the atorvastatin-use group and only 3 cases
used it for ]12 months. Albeit statistically significant,
this result should be interpreted carefully because this
figure is really too small to draw firm conclusions.
Conclusion
This study shows that use of atorvastatin ]12 months
may reduce 86% risk of esophageal cancer. Age, alcohol-
ism, and esophageal diseases are independent factors
significantly associated with esophageal cancer.
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